常规超声、免疫组化因子及BRAFV600E突变预测甲状腺乳头状癌中央区颈部淋巴结转移
该研究纳入225例连续手术的甲状腺乳头状癌患者,术前超声评估大小、成分、回声、形态、边缘、微钙化、多灶性、内部血流及包膜接触或侵犯,并检测细胞角蛋白19、人骨髓内皮细胞1、半乳糖凝集素3、甲状腺过氧化物酶及BRAFV600E突变。病理证实44%(99/225)存在中央区淋巴结转移,多因素分析显示病灶≤10mm、微钙化、内部血流、包膜接触或侵犯及BRAFV600E突变为独立危险因素,据此建立六阶段风险评分模型,各阶段中央区淋巴结转移率分别为0%(0/1)、0%(0/22)、7.4%(4/54)、48.6%(34/70)、71.2%(42/59)和100%(19/19)。
要点
- 病灶≤10mm、微钙化、内部血流、包膜接触或侵犯及BRAFV600E突变是中央区淋巴结转移的独立危险因素
- 风险评分=1.5×(病灶≤10mm)+1.9×(微钙化)+0.8×(内部血流)+3.0×(包膜接触或侵犯)+1.5×(BRAFV600E突变)
- 风险评分分六阶段,对应中央区淋巴结转移率分别为0%、0%、7.4%、48.6%、71.2%和100%
核心结论
- 甲状腺乳头状癌≤10mm、微钙化、内部血流、包膜接触或侵犯及BRAFV600E突变是中央区淋巴结转移的危险因素;该风险模型可能有助于甲状腺乳头状癌患者的治疗计划与管理。
研究设计与样本
- 连续纳入225例(225个甲状腺乳头状癌)接受手术的患者,术前超声评估大小、成分、回声、形态、边缘、微钙化、多灶性、内部血流及包膜接触或侵犯,并评估细胞角蛋白19、人骨髓内皮细胞1、半乳糖凝集素3、甲状腺过氧化物酶四种免疫组化因子及BRAFV600E突变,采用单因素和多因素分析筛选中央区淋巴结转移危险因素并建立风险模型,以病理为参考标准。
关键影像表现/征象
- 超声评估指标包括大小、成分、回声、形态、边缘、微钙化、多灶性、内部血流及包膜接触或侵犯。
- 病理证实44%(99/225)的甲状腺乳头状癌存在中央区淋巴结转移。
诊断标准与关键数值
- 多因素分析显示病灶≤10mm、微钙化、内部血流、包膜接触或侵犯及BRAFV600E突变为中央区淋巴结转移的独立危险因素。
- 风险评分=1.5×(病灶≤10mm)+1.9×(微钙化)+0.8×(内部血流)+3.0×(包膜接触或侵犯)+1.5×(BRAFV600E突变)。
- 风险评分分六阶段,对应中央区淋巴结转移率分别为0%(0/1)、0%(0/22)、7.4%(4/54)、48.6%(34/70)、71.2%(42/59)和100%(19/19)。
临床应用与阅片要点
- 术前超声发现病灶≤10mm、微钙化、内部血流、包膜接触或侵犯时,可结合BRAFV600E突变状态评估中央区淋巴结转移风险。
- 作者认为该风险模型可能有助于甲状腺乳头状癌患者的治疗计划与管理。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
The study was aimed at evaluating the correlation between central cervical lymph node metastasis (CLNM) in papillary thyroid carcinoma (PTC) patients and ultrasound (US) features, immunohistochemical factors and BRAFV600E mutation. A total of 225 consecutive patients (225 PTCs) who had undergone surgery were included. All PTCs were pre-operatively analysed by US with respect to size, components, echogenicity, shape, margins, microcalcification, multiple cancers or not, internal vascularity and capsule contact or involvement. The presence of four immunohistochemical factors, including cytokeratin 19, human bone marrow endothelial cell 1, galectin-3 and thyroid peroxidase, and BRAFV600E mutation was also evaluated. Univariate and multivariate analyses were performed to identify the risk factors for central CLNM, and a risk model was established. Pathologically, 44% (99/225) of the PTCs had central CLNMs. Multivariate analysis revealed that size ≤10mm, microcalcification, internal vascularity, capsule contact or involvement and BRAFV600E mutation were independent risk factors for central CLNM. The risk score for central CLNM was calculated as follows: risk score = 1.5 × (if lesion size ≤10 mm) + 1.9 × (if microcalcification) + 0.8 × (if internal flow) + 3.0 × (if capsule contact or involvement) + 1.5 × (if BRAFV600E mutation). The rating result was divided into six stages, and the relevant risk rates of central CLNM were 0% (0/1), 0% (0/22), 7.4% (4/54), 48.6% (34/70), 71.2% (42/59) and 100% (19/19), respectively. In conclusion, PTC ≤10mm, microcalcification, internal vascularity, capsule contact or involvement and BRAFV600E mutation are risk factors for central CLNM. The risk model may be useful in treatment planning and management of patients with PTCs.
引用
- Chen J, Li XL, Zhao CK, et al. Conventional Ultrasound, Immunohistochemical Factors and BRAFV600E Mutation in Predicting Central Cervical Lymph Node Metastasis of Papillary Thyroid Carcinoma. Ultrasound Med Biol. 2018. PMID: 30100099. doi:10.1016/j.ultrasmedbio.2018.06.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。